| Objective To investigate the effect of ganoderma lucidum plysaceharide (GLP) on myocardial remodeling through the phospho-serine/threonine kinase (p-Akt)/phospho-glycogen synthase kinase-3β (p-GSK3β)/ glycogen synthase kinase-3β (GSK3β) pathway in diabetic cardiomyopathy rats.Methods From December 2020 to December 2021, 90 SPF male SD rats were assigned into control, model, low-, medium-, high-dose GLP groups according to random number table method, 18 rats in each group. The modelgroup and GLP groups were fed with high-fat and high-sugar diet combined with intraperitoneal injection of low dose of streptozocin(STZ) solution (30 mg/kg) to induce diabetic cardiomyopathy rats model, 15 rats successfully modeled for experiments in each group.The low-, medium-and high-dose GLP groups were given 25, 50 and 100 mg/kg GLP solution (saline) by gavage according to the bodyweight of 10 mL/kg. The rats in the control group and the model group were given equal volume of saline solution daily for 4 weeks. Acomparison was made of blood glucose, body weight, left ventricular index, myocardial fibrosis levels, myocardial apoptosis levels,transforming growth factor-β1 (TGF-β1) in myocardial tissue, matrix metallopeptidase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) levels, and p-Akt, serine/threonine kinase (Akt), p-GSK3β, GSK3β protein expression levels.Results Compared with blood glucose, left ventricular index, collagen volume fraction (CVF), apoptosis index (AI) and myocardial TGF-β 1, MMP-2, and MMP-9 levels [(4.45±0.38) mmol/L, (2.21±0.18), (2.59±0.27)%, (2.17±0.24)%, (126.34±10.43) μg/L, (141.23±12.12) μg/L, (126.34±10.23) μg/L] inthe control group, the above indicators in the model group [(20.34±2.78) mmol/L, (3.46±0.23), (16.12±1.43)% , (20.32±1.78)% ,(257.65±18.15) μg/L, (268.43±19.3) μg/L, (347.65±23.15) μg/L], the low-dose GLP group [(16.36±1.12) mmol/L, (3.17±0.21), (13.17±1.27)%, (15.31±1.15)%, (214.46±17.44) μg/L, (227.18±17.36) μg/L, (302.46±23.48) μg/L],the middle-dose GLP group [(13.23±0.97)mmol/L, (2.84±0.18), (10.41±0.96)%, (12.18±1.02)%, (184.44±14.37) μg/L, (189.68±16.89) μg/L, (257.44±19.77) μg/L], and the high-dose GLP group [(9.84±1.01) mmol/L, (2.57±0.16), (7.36±0.62)%, (9.66±0.74)%, (163.17±11.54) μg/L, (152.74±15.23) μg/L, (176.17±12.45) μg/L] .were significantly increased, and rat body weight and p-Akt, p-GSK3β protein levels were significantly decreased (P< 0.05). Compared with model group, blood glucose, left ventricular index, CVF, AI, TGF-β1, MMP-2, and MMP-9 levels in the different GLP groups were significantly decreased, and rat body weight and p-Akt, p-GSK3β protein levels were significantly increased (P< 0.05). Blood glucose, left ventricular index, CVF, AI and TGF-β1, MMP-2, MMP-9 levels were decreased with GLP dose concentration, and rat body weight, p-Akt, p-GSK3β protein levels were increased with GLP dose concentration.Conclusion GLP can reduce DCM rats' blood sugar and weaken myocardial fibrosis and myocardial apoptosis, which may play a regulatory role by activation of relatedprotein expression in the p-Akt/p-GSK3β/GSK3β pathway. |
